Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa.

Jamieson L, Evans D, Berhanu R, Ismail N, Aucock S, Wallengren K, Long L.

BMC Public Health. 2019 Dec 5;19(1):1638. doi: 10.1186/s12889-019-7965-9.

2.

MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care.

Loveday M, Wallengren K, Reddy T, Besada D, Brust JCM, Voce A, Desai H, Ngozo J, Radebe Z, Master I, Padayatchi N, Daviaud E.

PLoS One. 2018 Apr 18;13(4):e0196003. doi: 10.1371/journal.pone.0196003. eCollection 2018.

3.

Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules.

Pan SJ, Tapley A, Adamson J, Little T, Urbanowski M, Cohen K, Pym A, Almeida D, Dorasamy A, Layre E, Young DC, Singh R, Patel VB, Wallengren K, Ndung'u T, Wilson D, Moody DB, Bishai W.

J Infect Dis. 2015 Dec 1;212(11):1827-34. doi: 10.1093/infdis/jiv312. Epub 2015 May 26.

4.

Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.

Loveday M, Wallengren K, Brust J, Roberts J, Voce A, Margot B, Ngozo J, Master I, Cassell G, Padayatchi N.

Int J Tuberc Lung Dis. 2015 Feb;19(2):163-71. doi: 10.5588/ijtld.14.0369.

5.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH.

Mycobact Dis. 2014 May 5;4:145.

6.

Association between health systems performance and treatment outcomes in patients co-infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: implications for TB programmes.

Loveday M, Padayatchi N, Wallengren K, Roberts J, Brust JC, Ngozo J, Master I, Voce A.

PLoS One. 2014 Apr 9;9(4):e94016. doi: 10.1371/journal.pone.0094016. eCollection 2014.

7.

The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: is it patient-centred?

Loveday M, Padayatchi N, Voce A, Brust J, Wallengren K.

Int J Tuberc Lung Dis. 2013 Oct;17(10 Suppl 1):56-59. doi: 10.5588/ijtld.13.0101.

8.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27.

9.

Polymorphisms in the gene that encodes the iron transport protein ferroportin 1 influence susceptibility to tuberculosis.

Baker MA, Wilson D, Wallengren K, Sandgren A, Iartchouk O, Broodie N, Goonesekera SD, Sabeti PC, Murray MB.

J Infect Dis. 2012 Apr 1;205(7):1043-7. doi: 10.1093/infdis/jis026. Epub 2012 Feb 21.

PMID:
22357659
10.

Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa.

Loveday M, Wallengren K, Voce A, Margot B, Reddy T, Master I, Brust J, Chaiyachati K, Padayatchi N.

Int J Tuberc Lung Dis. 2012 Feb;16(2):209-15. doi: 10.5588/ijtld.11.0401.

11.

Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007.

Wallengren K, Scano F, Nunn P, Margot B, Buthelezi SS, Williams B, Pym A, Samuel EY, Mirzayev F, Nkhoma W, Mvusi L, Pillay Y.

Emerg Infect Dis. 2011 Oct;17(10):1913-6. doi: 10.3201/eid1710.100952.

12.

Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa.

Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M.

J Clin Microbiol. 2011 Jan;49(1):385-8. doi: 10.1128/JCM.01378-10. Epub 2010 Oct 27.

13.

The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.

Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D.

PLoS Med. 2010 Jun 22;7(6):e1000296. doi: 10.1371/journal.pmed.1000296.

14.

Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area.

Schreiber YS, Herrera AF, Wilson D, Wallengren K, Draper R, Muller J, Dawood H, Doucette S, Cameron DW, Alvarez GG.

Int J Tuberc Lung Dis. 2009 Oct;13(10):1274-80.

PMID:
19793433
15.

The A17L gene product of vaccinia virus is exposed on the surface of IMV.

Wallengren K, Risco C, Krijnse-Locker J, Esteban M, Rodriguez D.

Virology. 2001 Nov 10;290(1):143-52.

16.

[Basic courses and graduate courses--are these two never going to meet?].

Wallengren K.

Lakartidningen. 2002 Jan 31;99(5):433. Swedish. No abstract available.

PMID:
11881259
17.

Minimal exclusion of plasma membrane proteins during retroviral envelope formation.

Hammarstedt M, Wallengren K, Pedersen KW, Roos N, Garoff H.

Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7527-32.

18.

Localization of actin in Moloney murine leukemia virus by immunoelectron microscopy.

Nermut MV, Wallengren K, Pager J.

Virology. 1999 Jul 20;260(1):23-34.

Supplemental Content

Loading ...
Support Center